These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25614274)

  • 21. Osteoporosis in men: epidemiology and treatment with denosumab.
    Sidlauskas KM; Sutton EE; Biddle MA
    Clin Interv Aging; 2014; 9():593-601. PubMed ID: 24748777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab: mechanism of action and clinical outcomes.
    Hanley DA; Adachi JD; Bell A; Brown V
    Int J Clin Pract; 2012 Dec; 66(12):1139-46. PubMed ID: 22967310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis.
    Fontalis A; Kenanidis E; Prousali E; Potoupnis M; Tsiridis E
    Expert Opin Drug Saf; 2018 Apr; 17(4):413-428. PubMed ID: 29350565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When and how to stop denosumab therapy in a patient with osteoporosis.
    Goulden EL; Crowley RK
    Clin Endocrinol (Oxf); 2023 May; 98(5):649-653. PubMed ID: 35470448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Updates of denosumab, anti-RANKL antibody for osteoporosis].
    Tokuyama N; Tanaka S
    Clin Calcium; 2014 Jan; 24(1):85-91. PubMed ID: 24369284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis.
    Sutton EE; Riche DM
    Ann Pharmacother; 2012; 46(7-8):1000-9. PubMed ID: 22837347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RANKL as a target for the treatment of osteoporosis.
    Matsumoto T; Endo I
    J Bone Miner Metab; 2021 Jan; 39(1):91-105. PubMed ID: 33057808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How Long to Treat with Denosumab.
    Costa AG; Bilezikian JP
    Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
    Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
    Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role and efficacy of denosumab in the treatment of osteoporosis: an update.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Mar; 10(2):205-17. PubMed ID: 21208140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab: recent update in postmenopausal osteoporosis.
    Silva I; Branco JC
    Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies for treating osteoporosis.
    Faienza MF; Chiarito M; D'amato G; Colaianni G; Colucci S; Grano M; Brunetti G
    Expert Opin Biol Ther; 2018 Feb; 18(2):149-157. PubMed ID: 29113523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.